<http://schema.org/description>
"After AstraZeneca reportedly rebuffed Pfizer&amp;#39;s huge acquisition offer, we look into what makes the former&amp;#39;s pipeline attractive to Pfizer and investors."^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.fool.com/investing/general/2014/04/24/is-this-struggling-drugmaker-worth-100-billion.aspx>